Latest Headlines

Latest Headlines

Pfizer/BMS data poses threat to BI's Pradaxa

When several drugmakers are developing similar new drugs, there's always a lot of talk about which one will reach the market first. In the case of clot-busting drugs to compete with the old standby

UPDATED: Regeneron eye drug gets green flag at AdComm

Regeneron Pharmaceuticals ($REGN) has passed a key test at an FDA advisory committee meeting on its experimental eye drug. The expert panel voted unanimously that the treatment, called VEGF Trap-Eye,

High Court clears way for Baycol class action

Bayer will have to fight a potential class action suit over its cholesterol drug Baycol. The U.S. Supreme Court negated a Minnesota judge's ban on class actions over the drug, allowing two West

Are drugmakers suffering from complexity?

Complexity is generally considered to be a good thing. In business, companies that grow tend to become more complex; the former doesn't seem to be possible without the latter. But there's such a

'Bad complexity' hinders Bayer more than other firms

GlaxoSmithKline and Sanofi have lower levels of "bad complexity" than Novartis, J&J, Pfizer and Roche. But it's Bayer that struggles the most with excessive complexity, says a report from the

FDA reviews risks of drospirenone contraceptives

The FDA is taking a look at new data suggesting higher risks for certain birth control pills. In the wake of two new studies, the agency said it would review the evidence on contraceptives containing

Price pressure, new rivals force Bayer's MS move

Last week, Bayer said it would shut down production of a key drug in California, a move that would claim some 540 jobs by 2013. This week, the company is confirming that production will go to

Bayer to cut roughly 540 jobs in CA

Bayer HealthCare is winding down production of its blockbuster multiple sclerosis drug Betaseron in Emeryville, CA, and moving it to Germany. The move will cost about 540 people their jobs beginning

Bayer bias suit grows with new plaintiffs

The gender bias suit against Bayer just got bigger. Two more plaintiffs have joined the case, which claims the drugmaker discriminated against women by paying and promoting them inequitably and by

Is a Bayer 'merger of equals' in the stars?

Bayer CEO Marijn Dekkers (photo) isn't desperate to make a match. But if the right company came along? Well, he might just do a deal. In an interview with Bloomberg, Dekkers said he'd like to bolster